Can a woman with intestinal tuberculosis and a history of pulmonary tuberculosis be treated using an anti‑TB regimen that omits pyrazinamide?

Recommendation

Yes—but only if pyrazinamide is contraindicated or the organism is naturally resistant (e.g., M. bovis); in that case, treat with isoniazid + rifampicin for 9 months, adding ethambutol for the first 2 months; otherwise, include pyrazinamide because it shortens therapy and improves cure rates, which best protects morbidity, mortality, and quality of life 1.

How to decide (algorithm)

• Confirm need to omit pyrazinamide
  • Absolute reason to omit:
    • Infection due to M. bovis (intrinsically PZA‑resistant): Use 9 months of rifampicin + isoniazid, with 2 months of initial ethambutol 1.
    • True pyrazinamide intolerance/toxicity or clear contraindication (e.g., severe hepatotoxicity): Extend total duration to 9 months; give ethambutol for first 2 months 1.
• If no clear reason to omit pyrazinamide:
  • Use standard regimen including pyrazinamide for 2 months (HRZE → HR 4 months) because it shortens therapy from 9 to 6 months and is the global standard for drug‑susceptible TB, improving adherence and outcomes (lower relapse → better morbidity/mortality/QoL) 2, 3.

Extrapulmonary (intestinal) TB specifics

• Most non‑respiratory TB (including intestinal) can follow the same 6‑month short‑course regimen when pyrazinamide is tolerable; if pyrazinamide is omitted, extend to 9 months as above to reduce relapse risk 1.

Nuances and pitfalls

• Prior pulmonary TB or higher resistance risk: ensure initial ethambutol until susceptibilities return; if isoniazid resistance is detected, do not simply omit pyrazinamide—adjust per resistance guidance; but in true pyrazinamide omission, extend to 9 months to protect cure and relapse (morbidity/QoL) 1, 4.
• Do not use pyrazinamide‑free 6‑month regimens for drug‑susceptible disease; evidence and guidelines support 9 months if pyrazinamide cannot be given 1, 4.
• If organism is M. bovis: never use pyrazinamide; regimen is R+H for 9 months with 2 months E upfront 1.
• Hepatotoxicity risk: if pyrazinamide caused significant liver injury, omit it and extend duration; monitor liver tests closely to avoid treatment interruptions that worsen outcomes 1.

One‑page regimen choices (prioritizing morbidity/mortality/QoL)

• Pyrazinamide tolerated: 2HRZE + 4HR (total 6 months) 2, 1.
• Pyrazinamide contraindicated or M. bovis: 2HRE + 7HR (total 9 months) 1.